TOKYO - Takeda Pharmaceutical Co. said Wednesday it has started a clinical trial of a COVID-19 vaccine developed by U.S. biotechnology firm Novavax Inc. in Japan, planning to domestically produce and supply it in the second half of 2021.
Sorry. This article is no longer available.
Sorry, this article was first published more than three months ago and is temporarily unavailable.
Once the upcoming introduction of a paid membership system is fully operational, paid members will have access to all our stories.
Free Membership Provides
Newsletter from Editorial Team and access to archive articles from past three months.
By continuing, you agree to the Terms of Use,
and Privacy Policy.
